当前位置:首页>产品中心>单抗/多抗>Anti-Human CDH1/CDH11 Recombinant Antibody, PE|抗人CDH1/CDH11重组抗体, PE标记(靶标:人E-钙黏蛋白/钙黏蛋白11(PE标记))

Anti-Human CDH1/CDH11 Recombinant Antibody, PE|抗人CDH1/CDH11重组抗体, PE标记(靶标:人E-钙黏蛋白/钙黏蛋白11(PE标记))

  • 货号:RB9THY460327
  • 价格:面议
  • 点击:246

产品介绍

产品参数

形态Liquid
宿主种属Mouse
克隆性Monoclonal
抗体亚型IgG2a, kappa
内毒素水平Please contact with the lab for this information.
应用FCM
种属反应性Human
靶标CAM 120/80, CD324, CDH1, CDHE, Cadherin-1, E-Cad/CTF1, E-Cad/CTF2, E-Cad/CTF3, E-cadherin, Epithelial cadherin, UVO, Uvomorulin, CDH11, Cadherin-11, OB-cadherin, OSF-4, Osteoblast cadherin
标记/偶联物PE
储存缓冲液0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300.
稳定性和储存Store at 4°C for 12 months. Protect from light. Do not freeze.
登录号P12830, P55287
背景信息

Cadherin-1 (CDH1/CDH11) is a ~97 kDa protein. Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. CDH1 is involved in mechanisms regulating cell-cell adhesions, mobility and proliferation of epithelial cells. Promotes organization of radial actin fiber structure and cellular response to contractile forces, via its interaction with AMOTL2 which facilitates anchoring of radial actin fibers to CDH1 junction complexes at the cell membrane. Plays a role in the early stages of desmosome cell-cell junction formation via facilitating the recruitment of DSG2 and DSP to desmosome plaques.

1. Meigs, TE. et al. (2002) The Journal of biological chemistry 277, 24594-600. PMID: 11976333
2. Shafraz, O. et al. (2018) eLife 7. PMID: 29999492
备注For flow cytometric staining, the suggested use of this reagent is 0.5 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application. For research use only.
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Ixekizumab Non-Neutralizing Recombinant Antibody |抗依奇珠单抗非中和重组抗体(靶标:依奇珠单抗非中和抗体) 388
Anti-Ixekizumab Non-Neutralizing Recombinant Antibody |抗依奇珠单抗非中和重组抗体(靶标:依奇珠单抗非中和抗体) 387
Anti-Ixekizumab Non-Neutralizing Recombinant Antibody |抗依奇珠单抗非中和重组抗体(靶标:依奇珠单抗非中和抗体) 573
Anti-Ixekizumab Neutralizing Recombinant Antibody |抗依奇珠单抗中和重组抗体(靶标:依奇珠单抗中和抗体) 545
Anti-Ixekizumab Neutralizing Recombinant Antibody |抗依奇珠单抗中和重组抗体(靶标:依奇珠单抗中和抗体) 485
Anti-Ixekizumab Neutralizing Recombinant Antibody |抗依奇珠单抗中和重组抗体(靶标:依奇珠单抗中和抗体) 450
Anti-Daratumumab Non-Neutralizing Recombinant Antibody|抗达雷妥尤单抗非中和重组抗体(靶标:达雷妥尤单抗非中和抗体) 515
Anti-Daratumumab Neutralizing Recombinant Antibody |抗达雷妥尤单抗中和重组抗体(靶标:达雷妥尤单抗中和抗体) 564
Anti-Daratumumab Neutralizing Recombinant Antibody |抗达雷妥尤单抗中和重组抗体(靶标:达雷妥尤单抗中和抗体) 506
Anti-Daratumumab Neutralizing Recombinant Antibody |抗达雷妥尤单抗中和重组抗体(靶标:达雷妥尤单抗中和抗体) 627
Anti-Daratumumab Neutralizing Recombinant Antibody |抗达雷妥尤单抗中和重组抗体(靶标:达雷妥尤单抗中和抗体) 587
Anti-Avelumab Non-Neutralizing Recombinant Antibody |抗阿维鲁单抗非中和重组抗体(靶标:阿维鲁单抗非中和抗体) 303
Anti-Avelumab Non-Neutralizing Recombinant Antibody |抗阿维鲁单抗非中和重组抗体(靶标:阿维鲁单抗非中和抗体) 375
Anti-Avelumab Non-Neutralizing Recombinant Antibody |抗阿维鲁单抗非中和重组抗体(靶标:阿维鲁单抗非中和抗体) 555
Anti-Avelumab Non-Neutralizing Recombinant Antibody |抗阿维鲁单抗非中和重组抗体(靶标:阿维鲁单抗非中和抗体) 386
Anti-Avelumab Neutralizing Recombinant Antibody |抗阿维鲁单抗中和重组抗体(靶标:阿维鲁单抗中和抗体) 576
Anti-Avelumab Neutralizing Recombinant Antibody |抗阿维鲁单抗中和重组抗体(靶标:阿维鲁单抗中和抗体) 374
Anti-Camrelizumab Neutralizing Recombinant Antibody |抗卡瑞利珠单抗中和重组抗体(靶标:卡瑞利珠单抗中和抗体) 623
Anti-Camrelizumab Neutralizing Recombinant Antibody |抗卡瑞利珠单抗中和重组抗体(靶标:卡瑞利珠单抗中和抗体) 604
Anti-Camrelizumab Neutralizing Recombinant Antibody |抗卡瑞利珠单抗中和重组抗体(靶标:卡瑞利珠单抗中和抗体) 540
总计 33037 个记录,共 1652 页,当前第 1648 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00